Adare Pharmaceuticals   Report issue

For profit Phase 3
Founded: Lawrenceville NJ United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03191864
First Marketed Drug
2015
potassium chloride (klor-con)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Adare Pharmaceuticals, Inc. | ADARE PHARMS INC

Active Ingredients

Marketed Drugs (3)

dexmethylphenidate (focalin) (2018)

potassium chloride (klor-con) (2004)

propranolol (inderal) (2011)

Drugs in Phase 3 Trials (1)

fluticasone (cutivate) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eosinophilic Esophagitis (Phase 3)

Esophagitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1